Barry Shin Email
EVP, Chief Operating Officer and Chief Financial Officer . Trevena
How to contact Barry Shin
Join and see Barry's contact info for free!Current Roles
Employees:
49Revenue:
$7.5MAbout
Approximately 40% of modern medicinal products target GPCRs and GPCRs remain the largest class of targets currently under clinical evaluation. Currently marketed GPCR drugs suffer significant problems such as limited efficacy and undesirable adverse effects, which generally limit their overall use. Furthermore, there are many GPCRs linked to disease that cannot be translated into medicines because of specific target-related adverse effects. Trevena’s novel drug discovery approach combines a powerful, proprietary and efficient drug discovery platform with the Company’s extensive discovery and development experience to yield a rich pipeline of breakthrough medicines. Trevena’s drug discovery technology is based on the groundbreaking research from the laboratories of leading scientists in the field - Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. of Duke University Medical Center.Trevena Address
955 Chesterbrook BlvdKing of Prussia, PA
United States